参考文献/References:
[1]王书航,王洁.2018年V3版NCCN非小细胞肺癌指南更新要点解读[J].华西医学,2018,33(4):388-392.[2]Himelstein AL,Foster JC,Khatcheressian JL,et al.Effect of longerinterval vs standard dosing of zoledronic acid on skeletal events inpatients with bone metastases: a randomized clinical trial[J].JAMA,2017,317(1):48-58.[3]陈滔,谭兴春.唑来膦酸联合化疗对非小细胞肺癌骨转移临床疗效及炎性因子水平的影响[J].药物评价研究,2019,42(6):163-166.[4]蒋桂成,林贵山,崔同建.姑息性放疗联合三阶梯止痛原则治疗非小细胞肺癌骨转移疼痛临床分析[J].肿瘤研究与临床,2018,30(12):851-854,859.[5]王伟.唑来膦酸对晚期非小细胞肺癌骨转移患者的疗效及VEGF-C和COX2水平的影响[J].医学临床研究,2019,36(4):640-642.[6]Qiu H,Yi T,Zhang L.Efficacy analysis of zoledronic acid combined with radiotherapy and combined with chemotherapy forbone metastasis of non-small cell lung cancer[J].Cancer Res,2017,29(7):437-441.[7]苏世先,刘前前,江美林,等.不同方案治疗肿瘤骨转移性疼痛的临床效果比较[J].实用癌症杂志,2017,31(10):1728-1730.[8]廖立潇,石大友,欧阳俊,等.沙利度胺联合地塞米松预防放射性肺炎的疗效分析[J].江西医药,2017,52(12):1352-1354.[9]周洋,邹华伟.唑来膦酸联合培美曲塞对肺腺癌细胞的体外抗肿瘤作用[J].山东医药,2017,56(1):35-37.[10]魏伟,张刚,杨明州,等.唑来膦酸联合苦参碱治疗晚期前列腺癌骨转移的疗效[J].国际泌尿系统杂志,2017,37(5): 646-648.[11]Andronis L,Goranitis I,Bayliss S,et al.Costeffectiveness of treatments for the management of bonemetastases: A systematic literature review[J].Pharmacoeconomics,2018,36(3):301-322.[12]杨志新,杨磊,钱阳晶.唑来膦酸对骨质疏松患者骨痛、骨密度和血清骨代谢标志物的影响[J].解放军医药杂志,2017,29(4):85-88.[13]梁坤,戴儒奇.89SrCl2联合唑来膦酸治疗前列腺癌骨转移的临床疗效与安全性观察[J].东南大学学报,2017,36(1):82-85.[14]宋亚琪,牛凤玲,林婷,等.唑来膦酸预防内分泌治疗所致绝经前乳腺癌患者骨丢失的作用[J].海南医学,2018,29(1):53-55.
相似文献/References:
[1]牟 婷,张朝阳.胰岛素联合唑来膦酸治疗糖尿病骨质疏松症对患者血清指标的影响[J].医学信息,2019,32(22):135.[doi:10.3969/j.issn.1006-1959.2019.22.045]
MU Ting,ZHANG Chao-yang.Effect of Insulin Combined with Zoledronic Acid on Serum Markers in Patients with Diabetic Osteoporosis[J].Journal of Medical Information,2019,32(21):135.[doi:10.3969/j.issn.1006-1959.2019.22.045]
[2]李 博.唑来膦酸联合放疗治疗恶性肿瘤骨转移患者的效果[J].医学信息,2020,33(09):138.[doi:10.3969/j.issn.1006-1959.2020.09.044]
YU Shou-jie,JIA Qian.The Effect of Zoledronic Acid Combined with Radiotherapy in Patients with Bone Metastases from Malignant TumorsLI Bo[J].Journal of Medical Information,2020,33(21):138.[doi:10.3969/j.issn.1006-1959.2020.09.044]
[3]黄应钟,杨立进.序贯抗骨质疏松对老年股骨粗隆间骨折愈合时间及再骨折的影响[J].医学信息,2021,34(18):94.[doi:10.3969/j.issn.1006-1959.2021.18.024]
HUANG Ying-zhong,YANG Li-jin.The Effect of Sequential Anti-osteoporosis on the Healing Time ofIntertrochanteric Fracture and Re-fracture in the Elderly[J].Journal of Medical Information,2021,34(21):94.[doi:10.3969/j.issn.1006-1959.2021.18.024]
[4]朱道信,罗志环,陈少健,等.唑来膦酸联合骨化三醇对骨质疏松症患者骨密度及骨代谢相关指标的影响[J].医学信息,2021,34(23):162.[doi:10.3969/j.issn.1006-1959.2021.23.049]
ZHU Dao-xin,LUO Zhi-huan,CHEN Shao-jian,et al.Effect of Zoledronic Acid Combined with Calcitriol on Bone Mineral Density and Bone Metabolism in Patients with Osteoporosis[J].Journal of Medical Information,2021,34(21):162.[doi:10.3969/j.issn.1006-1959.2021.23.049]
[5]崔宁宁,穆春梅,王 文,等.唑来膦酸联合经皮穿刺椎体后凸成形术治疗骨质疏松性椎体压缩骨折临床疗效的Meta分析[J].医学信息,2023,36(20):53.[doi:10.3969/j.issn.1006-1959.2023.20.010]
CUI Ning-ning,MU Chun-mei,WANG Wen,et al.Meta-analysis of Clinical Efficacy of Zoledronic Acid Combined with Percutaneous Kyphoplasty in the Treatment of Osteoporotic Vertebral Compression Fractures[J].Journal of Medical Information,2023,36(21):53.[doi:10.3969/j.issn.1006-1959.2023.20.010]
[6]张克斌,杜 杰,彭 英.应用唑来膦酸预防实体瘤骨相关事件的疗效及生存研究[J].医学信息,2024,37(01):109.[doi:10.3969/j.issn.1006-1959.2024.01.018]
ZHANG Ke-bin,DU Jie,PENG Ying.Study on the Efficacy and Survival of Zoledronic Acid in Preventing Skeletal Related Events in Solid Tumors[J].Journal of Medical Information,2024,37(21):109.[doi:10.3969/j.issn.1006-1959.2024.01.018]